Literature DB >> 11821529

Thrombopoietin: the novel hepatic hormone.

Eva-Maria Wolber1, Wolfgang Jelkmann.   

Abstract

The glycoprotein thrombopoietin (TPO) is the major stimulator of megakaryopoiesis and platelet production. Hepatocytes express TPO mRNA at a constant rate. The plasma TPO level is inversely correlated to the mass of megakaryocytes and platelets, which degrade the hormone following its binding to specific membrane receptors.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11821529     DOI： 10.1152/physiologyonline.2002.17.1.6

Source DB:  PubMed          Journal:  News Physiol Sci        ISSN： 0886-1714


  19 in total

Review 1.  The pharmacology and clinical application of thrombopoietin receptor agonists.

Authors:  Caizheng Li; Li Zheng
Journal:  Int J Hematol       Date:  2014-09-18       Impact factor: 2.490

2.  Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide.

Authors:  John H Baird; Caterina P Minniti; Jung-Min Lee; Xin Tian; Colin Wu; Mary Jackson; Shoaib Alam; James G Taylor; Gregory J Kato
Journal:  Br J Haematol       Date:  2014-11-06       Impact factor: 6.998

Review 3.  Management of Thrombocytopenia in Patients with Chronic Liver Disease.

Authors:  Sammy Saab; Robert S Brown
Journal:  Dig Dis Sci       Date:  2019-04-22       Impact factor: 3.199

4.  A hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brain.

Authors:  Hannelore Ehrenreich; Martin Hasselblatt; Friederike Knerlich; Nico von Ahsen; Sonja Jacob; Swetlana Sperling; Helge Woldt; Katalin Vehmeyer; Klaus-Armin Nave; Anna-Leena Sirén
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-10       Impact factor: 11.205

5.  A network map of thrombopoietin signaling.

Authors:  Firdous A Bhat; Jayshree Advani; Aafaque Ahmad Khan; Sonali Mohan; Arnab Pal; Harsha Gowda; Prantar Chakrabarti; T S Keshava Prasad; Aditi Chatterjee
Journal:  J Cell Commun Signal       Date:  2018-07-24       Impact factor: 5.782

6.  Population Pharmacokinetic and Pharmacodynamic Modeling of Lusutrombopag, a Newly Developed Oral Thrombopoietin Receptor Agonist, in Healthy Subjects.

Authors:  Takayuki Katsube; Toru Ishibashi; Takeshi Kano; Toshihiro Wajima
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

7.  Inhibition of megakaryocyte development in the bone marrow underlies dengue virus-induced thrombocytopenia in humanized mice.

Authors:  Aishwarya Sridharan; Qingfeng Chen; Kin Fai Tang; Eng Eong Ooi; Martin L Hibberd; Jianzhu Chen
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

8.  The uORF-containing thrombopoietin mRNA escapes nonsense-mediated decay (NMD).

Authors:  Clemens Stockklausner; Stephen Breit; Gabriele Neu-Yilik; Nicole Echner; Matthias W Hentze; Andreas E Kulozik; Niels H Gehring
Journal:  Nucleic Acids Res       Date:  2006-05-05       Impact factor: 16.971

9.  The Eltrombopag antitumor effect on hepatocellular carcinoma.

Authors:  Tomohiro Kurokawa; Soichiro Murata; Yun-Wen Zheng; Kenichi Iwasaki; Keisuke Kohno; Kiyoshi Fukunaga; Nobuhiro Ohkohchi
Journal:  Int J Oncol       Date:  2015-09-23       Impact factor: 5.650

10.  Signals and cells involved in regulating liver regeneration.

Authors:  Liang-I Kang; Wendy M Mars; George K Michalopoulos
Journal:  Cells       Date:  2012-12-13       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.